AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key
AstraZeneca is in the midst of a concerted push in oncology, but many of its top contenders are in crowded classes. The firm sees its future in the possibilities of combinations with immunotherapies.
You may also be interested in...
Quick path to lung cancer approval may not happen for durvalumab, but AstraZeneca could make its immuno-oncology debut with first CTLA-4/PD-L1 combination. Outlook in nephrology is also looking good, firm says at pipeline review.
Approved two months early, tyrosine kinase inhibitor’s labeling reflects 14.7-month progression-free survival improvement in patients with differentiated thyroid cancer, almost triple the benefit seen with Bayer/Amgen’s sorafenib.
U.S. President Paul Hudson says AstraZeneca is building specialty commercial team ahead of new oncology launches; MedImmune seals new deals in its quest for winning combinations in immuno-oncology.